# A Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Combination Therapy of T-614 and Methotrexate in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate

> **NCT00965757** · PHASE3 · COMPLETED · sponsor: **Eisai Co., Ltd.** · enrollment: 253 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** T-614
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00965757
- **Lead sponsor:** Eisai Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-07-31
- **Primary completion:** 2011-09-30
- **Final completion:** 2011-09-30
- **Target enrollment:** 253 (ACTUAL)
- **Last updated:** 2021-12-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00965757

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00965757, "A Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Combination Therapy of T-614 and Methotrexate in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00965757. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*